Goncalves Miguel, Schuler Patrick, Hackenberg Stephan
Klinik und Poliklinik für Hals-Nasen-Ohrenheilkunde, Kopf- und Hals-Chirurgie, Universitätsklinikum Würzburg, Josef-Schneider-Straße 11, 97080, Würzburg, Deutschland.
Klinik für Hals-Nasen-Ohrenheilkunde, Kopf- und Halschirurgie, Universitätsklinikum Ulm, Ulm, Deutschland.
HNO. 2024 Dec;72(12):868-875. doi: 10.1007/s00106-024-01526-8. Epub 2024 Oct 22.
At the 2024 international cancer congress of the American Society of Clinical Oncology (ASCO), studies on immuno-oncological therapeutic approaches for head and neck cancers once again took center stage. Following the trend of recent years, neoadjuvant immunotherapy has now reached a central role, and purely surgical studies have become increasingly scarce. This review article summarizes abstracts presented at the 2024 ASCO Annual Meeting that focus on surgical therapy or in which surgery was a significant component of the study protocol. As part of the combination therapies, study results on neoadjuvant treatment strategies are also presented. Additionally, promising new developments are discussed, including the treatment of laryngeal papillomatosis, new considerations on the necessary extent of neck dissection, follow-up care for human papillomavirus (HPV)-positive head and neck squamous cell carcinoma (HNSCC), and the prevention of platinum-induced inner ear hearing loss.
在2024年美国临床肿瘤学会（ASCO）国际癌症大会上，头颈部癌症免疫肿瘤治疗方法的研究再次成为焦点。顺应近年来的趋势，新辅助免疫疗法如今已占据核心地位，而单纯的外科手术研究变得越来越少。这篇综述文章总结了在2024年ASCO年会上发表的摘要，这些摘要聚焦于外科治疗，或者外科手术是研究方案的重要组成部分。作为联合治疗的一部分，还介绍了新辅助治疗策略的研究结果。此外，还讨论了有前景的新进展，包括喉乳头状瘤病的治疗、颈部淋巴结清扫所需范围的新考量、人乳头瘤病毒（HPV）阳性头颈部鳞状细胞癌（HNSCC）的后续护理，以及铂诱导的内耳听力损失的预防。
